CSA Is Not Optional Anymore: What FDA's Computer Software Assurance Guidance Means for Pharma in 202
May 15, 2026
When the FDA published its final Computer Software Assurance guidance in September 2022, most quality teams in APAC filed it under "interesting, deal with it later." Three years later has arrived. CSA is now the assumption baked into every fresh FDA inspection, every new SaaS vendor pitch, and every internal audit finding worth taking seriously.
For pharma, biotech, and medical device companies still running CSV the way it was done in 2014, the gap is widening. Not because the rules have changed dramatically, but because the cost of doing it the old way has finally caught up.
This is the conversation we're having with almost every client at Valina Services right now. Here is what we tell them.
What CSA actually is, and isn't
CSA stands for Computer Software Assurance. The clue is in the second word: assurance, not validation. The FDA's guidance, Computer Software Assurance for Production and Quality System Software, doesn't replace 21 CFR-Part 11 or EU-Annex 11. It doesn't loosen expectations around data integrity, audit trails, or electronic signatures. What it does is reset the question quality engineers should be asking.
Old CSV question: Have we documented everything?
CSA question: Have we tested the things that actually matter, in proportion to the risk they carry?
That is the entire shift in one sentence. The 200-page IQ/OQ/PQ binder isn't going away on its own. But it's no longer the price of admission. Critical thinking is.
Why the cost of legacy CSV is no longer survivable
Pull up the validation history of any GxP system installed before 2020 and you'll see the same thing: months of pre-execution authoring, weeks of execution, a deviation log nobody quite remembers closing, and a final report signed off six months after go-live. We've seen single LIMS validations chew through 1,800+ hours.
Compare that with what life sciences IT looks like in 2026. Veeva, MasterControl, AbCube, IQVIA, and dozens of niche SaaS vendors push releases every two to four weeks. Cloud-hosted QMS platforms update silently in the background. AI-assisted pharmacovigilance tools rewrite their own case-triage logic between minor versions.
You cannot validate a continuously-deployed system with a process designed for a CD-ROM. The arithmetic doesn't work.
The five things that actually change under CSA
Most of what you already do stays. These are the parts that move:
- Risk assessment becomes the first deliverable, not an afterthought. If the assessment isn't credible, nothing downstream will be defensible.
- Unscripted and exploratory testing become acceptable evidence for low-risk functions. Trained, qualified testers documenting what they did and what they observed. That is the standard now, not pre-written scripts for every click.
- Vendor evidence is allowed to do real work. If your SaaS provider's own test pack covers a function under a credible QMS, you don't have to re-test it. You do still need to verify their QMS is credible.
- Continuous assurance replaces big-bang revalidation for SaaS. Periodic review, release impact assessment, regression-on-change. These become the operating model.
- Documentation gets shorter on purpose. The goal is for an auditor to understand your reasoning in fifteen minutes, not fifteen hours.
Where APAC teams are getting this wrong
We work across Singapore, Malaysia, India, and increasingly Indonesia and Vietnam. The same three mistakes keep appearing.
The first is treating CSA as a permission slip to cut testing. It isn't. CSA tells you to test smarter, not less. Teams that show up to an HSA inspection with thin testing and the words "we're doing CSA now" tend not to enjoy the rest of that week.
The second is changing the testing approach without rewriting the SOPs. The validation SOP still says all test cases must be scripted, peer-reviewed, and executed with screen captures at every step. Until that document changes, your team is contractually obligated to ignore CSA, regardless of what leadership has decided.
The third is the alignment gap between Quality and IT. CSA is a risk-based methodology, and risk is a shared conversation. If your QA lead and your IT lead are not in the same room when the risk assessment is being drafted, the output will not be defensible.
How Valina supports the transition
Our CSA work falls into four buckets, and we tend to take clients through them in order:
- A readiness assessment that benchmarks your current validation lifecycle against the FDA's expectations, and against where HSA, CDSCO, NMPA, and PMDA inspectors are actually pushing in 2026.
- An updated validation framework: SOPs, templates, risk matrices, written to support CSA instead of quietly blocking it.
- Hands-on execution support for live projects, so your first CSA validation isn't a science experiment with your auditor as the test subject.
- Training for both Quality and IT run as working sessions rather than lectures. Nobody learns risk-based thinking from a slide deck.
We are agnostic about your platform. We've done this work with on-premises installations and with fully cloud-native rollouts. The methodology travels.
If you only do one thing this quarter
Pull your last three completed CSV efforts. Add up the engineering hours, the QA hours, and the elapsed calendar time. Then ask whether the resulting documentation would enable a new auditor to understand, in a single afternoon, which risks were addressed and why.
If the answer is no, and for most teams it is, that is the gap CSA is built to close. The longer it stays open, the more expensive it gets to close later.
Talk to us when you're ready. Contact Valina Services, and we will walk you through a CSA readiness assessment specific to your systems, your vendors, and the regulators you actually have to answer to.
This article provides general information and should not be considered regulatory advice. Always consult qualified professionals regarding your specific compliance requirements.